CANbridge Announces Financial Results and Corporate Updates for the Twelve Months Ended December 31, 2021

CANbridge Announces Approval of CAN108for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone

CANbridge Pharmaceuticals Appoints

Dr. Lan Hu as New Independent Director

CANbridge Reports Positive Top-Line CAN106 Phase 1 Data

Receives Approval to Treat Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Phase 1b/2 Trial in China

Results Suggest Complete Blockade of Complement Function

CAN106 Safe and Well-Tolerated

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA), for Alagille Syndrome, Accepted by China’s National Medical Products Administration

Priority Review Expected to be Granted